1
|
LEONARDI VITA, PALMISANO VALENTINA, PEPE ALESSIO, USSET ANTONELLA, MANUGUERRA GIOVANNA, SAVIO GIUSEPPINA, DE BELLA MANUELATAMBURO, LAUDANI AGATA, ALÙ MASSIMO, CUSIMANO MARIAPIA, SCIANNA CATERINA, GIRESI ARMANDO, AGOSTARA BIAGIO. Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study. Oncol Lett 2010; 1:749-753. [PMID: 22966374 PMCID: PMC3436426 DOI: 10.3892/ol_00000131] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2010] [Accepted: 05/13/2010] [Indexed: 11/06/2022] Open
Abstract
Pegylated liposomal doxorubicin (PLD) has the advantage of delivering active anthracycline directly to the tumor site, while exposing the patient to a lesser degree of doxorubicin-associated toxicities. Recently, a regimen in which paclitaxel is infused weekly over 1 h produced substantial antitumor activity with little myelosuppression. We designed a phase II trial to study the efficacy and toxicity of 10 mg/m(2) PLD on Days 1, 8 and 15, plus 70 mg/m(2) paclitaxel weekly in patients with untreated metastatic breast cancer and a high risk of cardiotoxicity. The study included 35 patients, with 31 (88.5%) evaluable for efficacy and 35 (100%) for toxicity. A total of 28 patients (80%) had two or more sites of disease. Overall, 4 complete and 16 partial responses were noted with an overall response rate of 64.5%, with 6 cases of stable and 5 cases of progressive disease. Toxicity was found to be manageable in that the only grade 3-4 side effects recorded were palmar-plantar erythrodysesthesia, 8.5%; mucositis, 2.8%; leucopenia, 12.5%; anemia, 2.8% and AST/ALT, 2.8%. No cardiotoxicity was observed. In conclusion, weekly PLD plus paclitaxel appears to be a well-tolerated and effective approach for metastatic breast cancer patients with a high risk of cardiotoxicity.
Collapse
Affiliation(s)
- VITA LEONARDI
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - VALENTINA PALMISANO
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - ALESSIO PEPE
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - ANTONELLA USSET
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - GIOVANNA MANUGUERRA
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - GIUSEPPINA SAVIO
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | | | - AGATA LAUDANI
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - MASSIMO ALÙ
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - MARIA PIA CUSIMANO
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - CATERINA SCIANNA
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - ARMANDO GIRESI
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| | - BIAGIO AGOSTARA
- Division Of Medical Oncology, Oncologic Department, Arnas Civico, Palermo, Italy
| |
Collapse
|